The Gastrointestinal Cancer Channel is supported with funding from Gilead Sciences (Silver) and Revolution Medicines (Silver).
VJOncology is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
AACR 2021 | Future targets for pancreatic cancer treatment
Michael Kim
• 8 Apr 2021
Michael Kim, MD, The University of Texas MD Anderson Cancer Center, Houston, TX, discusses the future of treatment for pancreatic cancer, highlighting potential targeting of pathways impacted by mutant p53 or oncogenic KRAS, such as CREB1, to prevent metastasis. This interview took place at the virtual American Association for Cancer Research (AACR) Annual Meeting 2021.
